PD-1/PD-L1 inhibitors have achieved good therapeutic effects in non-small cell lung cancer, melanoma, advanced Hodgkin’s lymphoma, liver cancer and breast cancer, amongst other types of cancer [16–19]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.